Genentech taps DualityBio's DUPAC ADC payload platform in a $45M upfront, $1B+ milestone deal to target payload-resistant tumors.
August 28, 2026 07:30 AM EDT
DealsChina
Roche bets $1B+ on DualityBio's ADC tech to tackle payload resistance
Ayisha Sharma
News Reporter
DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on…
Lonza Issues Exclusive, Target-Specific License to Antharis Therapeutics to Advance Next-Generation Dual Payload ADCs for…
Novartis pays $1.1B upfront (up to $1.5B total) for Myricx Bio, gaining its NMT inhibitor ADC payload platform and two…
Roche details its AI-driven pipeline gains and cautious token spending, while shelving Carmot's acmopatide after a $277M…
Roche plans to offer PathAI’s tools as part of an effort to improve cancer diagnosis and tailored treatment.
Roche's Genentech deepens its oncology pipeline bets by paying Astex $25M upfront (up to $490M+ milestones) for early breast…
